NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has priced a registered direct offering of 3.5 million equity units at $2 apiece, giving the transaction a $7 million value.

Each unit consists of one share of Cancer Genetics' common stock and one warrant to buy an additional share at an exercise price of $2.35. The warrants are exercisable six months after the date of issuance, and expire 18 months after issuance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.